Live Analysis
Novavax, Inc. (NVAX) is currently priced at $8, with a price change of -7 cents (-0.868%) from the previous close of $8.06. The trading volume is $2 million, representing a 48.6% increase compared to the average volume.
Earnings Overview
Novavax's latest quarterly earnings report, announced on Wednesday, February 25th, had a consensus estimate EPS of -0.66.
Cash Flow
Novavax reported a net change in cash of -$27.30 million, with operating cash flow at -$39.48 million. Cash at the end of the period stands at $256 million.
Income Statement
The company generated revenue of $147.14 million, resulting in a net income of $17.53 million. Earnings per share (EPS) and EPS diluted are both 11 cents.
Ratios
Key ratios include a gross profit margin of 82.87%, net profit margin of 11.91%, and a price-to-earnings ratio of 15.53.
Balance Sheet
Novavax's total current assets amount to $978.28 million, with total assets at $1.18 billion. Total liabilities stand at $1.30 billion, with net debt at $8.18 million.
This financial report provides insights into Novavax, Inc.'s current financial standing, performance, and key metrics.
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.